Press Releases

Found 227 Results
Page 1 of 23

Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology

In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]


Onxeo Announces its Financial Agenda for 2020

  Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]


Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.

Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]



Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000

The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]



Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]



Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform

This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]



Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy

  Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]



Page 1 of 23

Last updated on